IP Library Granted Patent US 9,707,126
Granted Patent B2
US 9,707,126 · App. 13/665,495 · Granted Jul 18, 2017

Systems and methods for corneal cross-linking with pulsed light

Inventors: Marc D. Friedman (Needham, MA); Pavel Kamaev (Lexington, MA); Evan Sherr (Ashland, MA); William Eddington (Cambridge, MA); Sara Rood-Ojalvo (Boston, MA); David Muller (Boston, MA)
Assignee: Avedro, Inc.
A61F9/0008A61F9/0079A61K31/525A61K41/00A61N5/062A61F9/013A61F2009/00872
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,707,126
App. No.
13/665,495
Granted
Jul 18, 2017
Kind
B2
Abstract

A method for controlling activation of Riboflavin applied to an eye includes applying the Riboflavin to a selected region of a cornea of the eye and initiating cross-linking activity in the selected region by activating the Riboflavin with pulsed light illumination. The pulsed light illumination has an irradiance, dose, and an on/off duty cycle. The irradiance, the dose, and the on/off duty cycle are adjusted in response to a determination of photochemical kinetic pathways for Riboflavin cross-linking activity and to control photochemical efficiency.

Claims (27)

1. A system for dynamically controlling an amount of cross-linking in a cornea, comprising:

a light source configured to activate cross-linking activity in a selected region of a cornea treated with a cross-linking agent, the light source being configured to deliver pulsed light illumination according to parameters including at least one of a frequency, an irradiance, a dose, or an on/off duty cycle; and

a controller coupled to the light source and configured to determine, based on a proposed set of the parameters for the light source, a calculated amount of cross-linking activity generated by reactions not involving singlet molecular oxygen and to adjust one or more of the parameters for the light source according at least to the calculated amount of cross-linking activity, in order to generate a desired amount of cross-linking activity in the selected region of the cornea,

wherein the controller is configured to cause the light source to apply the pulsed light illumination to the selected region of the cornea according at least to the one or more adjusted parameters.

2. The system of claim 1 , further comprising a delivery device configured to provide a concentration of oxygen to a surface of the cornea.

3. The system of claim 2 , wherein the delivery device is configured to first provide a first gas mixture that determines a first O 2 content in the cornea and secondly provide a second gas mixture that determines a second O 2 content in the cornea, the first gas mixture and the second gas mixture providing different amounts of O 2 , the delivery device providing dynamic control of cross-linking in the cornea.

4. The system of claim 2 , wherein the delivery device is configured to adjust an amount of oxygen delivered to the surface of the cornea according to the calculated amount of cross-linking activity generated by reactions not involving singlet molecular oxygen.

5. The system of claim 4 , wherein the delivery device is configured to reduce the amount of oxygen delivered to the surface of the cornea.

6. The system of claim 2 , wherein the delivery device is configured to provide a plurality of different, non-zero concentrations of oxygen to the surface of the eye, and the controller is configured to determine one of the plurality of concentrations of oxygen and cause the delivery device to provide the determined one of the plurality of concentrations of oxygen to the surface of the eye.

7. The system of claim 1 , wherein the irradiance is between approximately 1 mW/cm 2 to approximately 500 mW/cm 2 and the on/off duty cycle is between approximately 100/1 to approximately 1/100.

8. The system of claim 1 , wherein the pulsed light illumination has a pulse rate between approximately 0.1 Hz to approximately 1000 Hz.

9. The system of claim 1 , wherein the irradiance is between approximately 1 mW/cm 2 to approximately 1000 mW/cm 2 and the on/off duty cycle is between approximately 1000/1 to approximately 1/1000.

10. The system of claim 1 , wherein the pulsed light illumination has a pulse rate between approximately 1000 Hz to approximately 100,000 Hz.

11. The system of claim 1 , wherein the light source is further configured to apply the pulsed light illumination to different regions of the cornea according to different respective on/off duty cycles in response to the controller.

12. The system of claim 1 , wherein the light source is further configured to apply the pulsed light illumination and continuous wave illumination to different regions of the cornea according to different respective on/off duty cycles in response to the controller.

13. The system of claim 1 , wherein the pulsed light illumination corresponds to absorption peaks of the cross-linking agent.

14. The system of claim 1 , wherein the cross-linking agent includes Riboflavin with a concentration of Riboflavin between about 0.001% to about 1%.

15. The system of claim 14 , wherein the controller determines the calculated amount of cross-linking activity from reactions not involving singlet molecular oxygen by determining a reaction between triple excited Riboflavin and a corneal substrate.

16. The system of claim 15 wherein, the controller adjusts one or more of the parameters for the light source to control a rate of return of the reduced form of Riboflavin to the ground state.

17. The system of claim 14 , wherein the controller determines the calculated amount of cross-linking activity according at least to the following reactions:

Rf 3 *+SH→RfH.+S., and

2RfH.→Rf+RfH 2 ,

where Rf represents Riboflavin in a ground state, Rf represents Riboflavin in a triplet excited state, RfH. represents a radical form of Riboflavin, RfH 2 represents a reduced form of Riboflavin, SH represents a corneal substrate, and S. represent a corneal substrate radical.

18. The system of claim 1 , wherein the light source applies the pulsed light illumination according to a selected pattern corresponding to the selected region of the cornea.

19. The system of claim 1 , wherein the controller further determines the calculated amount of cross-linking activity based at least on one of a proposed concentration of the cross-linking agent or a proposed soak time for the treatment of the cross-linking agent.

20. The system of claim 1 , wherein the controller adjusts one or more of the parameters for the light source to increase an actual amount of cross-linking activity generated by reactions not involving singlet molecular oxygen.

21. The system of claim 1 , wherein the light source includes a digital micro-mirror device (DMD) including a plurality of mirrors, each mirror representing one or more pixels for the pulsed light illumination.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Nov 21, 2019
From: ORBIMED ROYALTY OPPORTUNITIES II, LP
To: AVEDRO, INC.
Reel/Frame 051080/0756 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT SERIAL NO. 14/140,184 PREVIOUSLY RECORDED AT REEL: 042167 FRAME: 0671. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 1, 2017
From: AVEDRO, INC.
To: ORBIMED ROYALTY OPPORTUNITIES II, LP
Reel/Frame 042390/0659 →
SECURITY INTEREST Recorded Apr 27, 2017
From: AVEDRO, INC.
To: ORBIMED ROYALTY OPPORTUNITIES II, LP
Reel/Frame 042167/0671 →
SECURITY AGREEMENT Recorded Feb 19, 2013
From: AVEDRO, INC.
To: VENTURE LENDING & LEASING VI, INC.
Reel/Frame 029835/0526 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2013
From: FRIEDMAN, MARC D.; KAMAEV, PAVEL; SHERR, EVAN; EDDINGTON, WILLIAM; ROOD-OJALVO, SARA; MULLER, DAVID
To: AVEDRO, INC.
Reel/Frame 029737/0957 →
Continuity (5)
Continuation In Part 12909228 · Oct 21, 2010
Provisional Application 61253736 · Oct 21, 2009
Provisional Application 61699226 · Sep 10, 2012
Provisional Application 61671798 · Jul 16, 2012
Related Publication 20130060187A1 · Mar 7, 2013